Publications
Evaluation of a cyclophilin inhibitor in Hepatitis C virus-infected chimeric mice in vivo
Viral Kinetics During 14-day Treatment with Debio-025 Demonstrate Efficient Blocking of Viral Replication in Different HCV Genotypes without Signs of…
The Reduction of both Cyclophilin B and HCV-RNA by the Cyclophilin Inhibitor Debio-025 Confirms the Importance of Cyclophilin B for…
Low Risk of Drug Interaction between the Cyclophilin Inhibitor Debio-025 and (Peg) IFNa/ribavirin in HCV
Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins
The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naïve HIV/HCV co-infected subjects
Non-immunosuppressive Cyclosporin Debio-025 with Interferon shows synergistic Anti-HCV Effect in Chimeric Mouse
Postconditioning and Debio-025 Prevent LV Remodelling and Reduce Mortaility Following Acute Myocardial Infarction in Mice